Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Launches Dayvigo in China, First Orexin Antagonist for Insomnia
August 19, 2025
- Sawai to Invest 19.5 Billion Yen to Strengthen Supply Capacity at Trust Pharmatech
August 19, 2025
- Padcev-Keytruda Combo Delivers Positive PIII Data in Bladder Cancer
August 18, 2025
- J&J’s New Bispecific Antibody Talvey Now Available in Japan
August 18, 2025
- Solasia Out-Licenses Cancer Drug to Singapore Firm Covering 19 Countries
August 18, 2025
- Mounjaro Tops Reps Detailing Chart in GP Market: Intage May Data
August 18, 2025
- Ultragenyx Japan Seeks Conditional Approval of Triheptanoin for LC-FAOD
August 12, 2025
- Japan Approves Pfizer/BioNTech’s LP.8.1-Tailored COVID Vaccines
August 12, 2025
- Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
- Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
- PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
- Kaken, Astria Ink Japan Deal for Navenibart for HAE Prophylaxis
August 8, 2025
- Ono, Seikagaku Finalize Japan Deal on Osteoarthritis Drug
August 8, 2025
- Japan Ethical Drug Sales Zoom 8.0% in June: Crecon
August 8, 2025
- Keytruda Leads Japan Drug Sales for 22nd Month: Encise
August 8, 2025
- Nxera Unveils Proprietary Pipeline Targeting Obesity and Weight Management
August 7, 2025
- Nippon Zoki Snags Japan Rights to Kagoshima University Offshoot’s Oncolytic Virus
August 6, 2025
- Eisai Sees Subcutaneous Autoinjector as Key to Boosting US Demand for Leqembi
August 6, 2025
- Takeda Taps AI Demand Forecasting for 70% of Products, Aims to Bolster Supply Reliability
August 6, 2025
- Sumitomo Files iPS Cell-Derived Dopaminergic Progenitor Cells in Japan
August 6, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…